Insilico Medicine

company

About

Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases.

  • 101 - 250

Details

Last Funding Type
Series B
Last Funding Money Raised
$37M
Industries
Artificial Intelligence,Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2014
Number Of Employee
101 - 250
Operating Status
Active

Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases. It pioneered the applications of the generative adversarial networks (GANs), reinforcement learning, transfer learning, and meta-learning for the generation of novel molecular structures for the diseases with known and unknown targets, and, unlike the other companies in the field, is developing the end-to-end pipeline covering every step of drug discovery, clinical trials analysis, and digital medicine. Insilico Medicine is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with Life Extension, the company launched a range of nutraceutical products, which were compounded using advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
5
$393M
Insilico Medicine has raised a total of $393M in funding over 2 rounds. Their latest funding was raised on Aug 10, 2022 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 10, 2022 Series D $35M 1 Detail
Jun 6, 2022 Series D $60M 1 Detail
Jun 22, 2021 Series C $255M 2 Detail
Sep 9, 2019 Series B $37M 2 Detail
Jun 18, 2018 Series A $6M 1 Detail

Investors

Number of Lead Investors
Number of Investors
2
Insilico Medicine is funded by 2 investors. Pavilion Capital and Lilly Asia Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Pavilion Capital Series D
Lilly Asia Ventures Series C